Alliance Pharma plc’s (APH) Buy Rating Reaffirmed at FinnCap
Several other brokerages also recently weighed in on APH. N+1 Singer reiterated a not rated rating on shares of Alliance Pharma plc in a report on Wednesday, September 13th. Investec began coverage on shares of Alliance Pharma plc in a report on Wednesday, September 13th. They issued a buy rating and a GBX 59 ($0.78) price target on the stock. Finally, Numis Securities Ltd reiterated a buy rating and issued a GBX 60 ($0.79) price target on shares of Alliance Pharma plc in a report on Wednesday, September 13th.
Alliance Pharma plc (LON APH) opened at GBX 58.25 ($0.77) on Tuesday. Alliance Pharma plc has a fifty-two week low of GBX 41.78 ($0.55) and a fifty-two week high of GBX 62.75 ($0.83).
The business also recently disclosed a dividend, which will be paid on Thursday, January 11th. Shareholders of record on Thursday, December 21st will be given a GBX 0.44 ($0.01) dividend. The ex-dividend date is Thursday, December 21st. This represents a yield of 0.84%.
About Alliance Pharma plc
Alliance Pharma plc is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in acquisition, marketing and distribution of pharmaceutical products. The Company operates in various business areas, such as Hydromol, secondary care, community and consumer products, established products and international.
Receive News & Ratings for Alliance Pharma plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliance Pharma plc and related companies with Analyst Ratings Network's FREE daily email newsletter.